Application of Monocyte Monolayer Assay technique to predict hyperhemolysis in patients with sickle cell disease.
作者信息
Cruz Dahra Teles, Conrado Marina C V, Mendrone Alfredo, Dinardo Carla L
机构信息
Fundação Pró-Sangue, São Paulo, SP, Brazil.
Fundação Pró-Sangue, São Paulo, SP, Brazil.
出版信息
Hematol Transfus Cell Ther. 2024 Oct-Dec;46(4):503-505. doi: 10.1016/j.htct.2023.07.004. Epub 2023 Aug 23.
Abstract
摘要
相似文献
1
Application of Monocyte Monolayer Assay technique to predict hyperhemolysis in patients with sickle cell disease.
Hematol Transfus Cell Ther. 2024 Oct-Dec;46(4):503-505. doi: 10.1016/j.htct.2023.07.004. Epub 2023 Aug 23.
2
A Fatal Case of Immune Hyperhemolysis with Bone Marrow Necrosis in a Patient with Sickle Cell Disease.
Hematol Rep. 2017 Mar 1;9(1):6934. doi: 10.4081/hr.2017.6934. eCollection 2017 Feb 23.
3
Recurrent Hyperhemolysis Syndrome in Sickle Cell Disease.
Cureus. 2021 May 12;13(5):e14991. doi: 10.7759/cureus.14991.
4
Acute Hyperhemolysis Syndrome in a Patient with Known Sickle Cell Anemia Refractory to Steroids and IVIG Treated with Tocilizumab and Erythropoietin: A Case Report and Review of Literature.
Hematol Rep. 2022 Jul 21;14(3):235-239. doi: 10.3390/hematolrep14030032.
5
Hyperhemolysis in sickle cell disease.
J Pediatr Hematol Oncol. 2014 Jan;36(1):e54-6. doi: 10.1097/MPH.0b013e31828e529f.
6
Hyperhemolysis during the evolution of uncomplicated acute painful episodes in patients with sickle cell anemia.
Transfusion. 2006 Jan;46(1):105-10. doi: 10.1111/j.1537-2995.2006.00679.x.
7
Hyperhemolysis Syndrome in Patients With Sickle Cell Disease.
Arch Pathol Lab Med. 2018 Nov;142(11):1425-1427. doi: 10.5858/arpa.2017-0251-RS.
8
Tocilizumab in the management of posttransfusion hyperhemolysis syndrome in sickle cell disease: The experience so far.
Transfusion. 2022 Mar;62(3):546-550. doi: 10.1111/trf.16805. Epub 2022 Jan 29.
9
Hyperbaric Oxygen Therapy during Pregnancy for Critical Anemia Secondary to Sickle Cell Disease with Post-Transfusion Hyperhemolysis: A Case Report.
Hematol Rep. 2024 Aug 30;16(3):552-558. doi: 10.3390/hematolrep16030053.
10
Clinical significance of RBC alloantibodies and autoantibodies in sickle cell patients who received transfusions.
Transfusion. 2002 Jan;42(1):37-43. doi: 10.1046/j.1537-2995.2002.00007.x.
本文引用的文献
1
American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support.
Blood Adv. 2020 Jan 28;4(2):327-355. doi: 10.1182/bloodadvances.2019001143.
2
Challenges in the treatment and prevention of delayed hemolytic transfusion reactions with hyperhemolysis in sickle cell disease patients.
Transfusion. 2019 May;59(5):1698-1705. doi: 10.1111/trf.15227. Epub 2019 Mar 8.
3
Massive autoimmune hemolysis documented by monocyte monolayer assay in a multiply transfused patient using reticulocytes isolated by simple centrifugation in microhematocrit tubes.
Transfusion. 2018 Jul;58(7):1578-1579. doi: 10.1111/trf.14511.
4
Defining the clinical relevance of red blood cell autoantibodies by Monocyte Monolayer Assay.
J Clin Lab Anal. 2018 Feb;32(2). doi: 10.1002/jcla.22274. Epub 2017 May 31.
5
RHD and RHCE genotyping by next-generation sequencing is an effective strategy to identify molecular variants within sickle cell disease patients.
Blood Cells Mol Dis. 2017 Jun;65:8-15. doi: 10.1016/j.bcmd.2017.03.014. Epub 2017 Mar 31.
6
Successful transfusion of antigen positive blood to alloimmunised patients using a monocyte monolayer assay.
Transfus Med. 2015 Apr;25(2):92-100. doi: 10.1111/tme.12189. Epub 2015 Mar 31.
7
Challenges of alloimmunization in patients with haemoglobinopathies.
Br J Haematol. 2012 Nov;159(4):394-404. doi: 10.1111/bjh.12061. Epub 2012 Oct 4.
8
Inflammation enhances consumption and presentation of transfused RBC antigens by dendritic cells.
Blood. 2007 Oct 1;110(7):2736-43. doi: 10.1182/blood-2007-03-083105. Epub 2007 Jun 25.
9
Predicting the clinical significance of red cell alloantibodies using a monocyte monolayer assay.
Transfusion. 1987 Nov-Dec;27(6):449-52. doi: 10.1046/j.1537-2995.1987.27688071692.x.
Zotero 插件